FDA Approves Novel Treatment for KRAS-Mutated Ovarian Cancer
, 2025-05-08 20:02:00 The US Food and Drug Administration (FDA) has granted accelerated approval of combination avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for the treatment of certain patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). Specifically, approval is for adults who received at least one prior systemic therapy, including a platinum-based regimen,…